Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
Eduardo Mysler, Samar A. Al-Emadi, C. A. Connell, V. Strand et al.
Citations
1 citations
Journal
BMJ Open
Topics
Rheumatoid Arthritis Research and Therapies
Field-Weighted Citation Impact (FWCI)
1.67
article
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
Eduardo Mysler, Samar A. Al-Emadi, C. A. Connell, V. Strand, David Gruben, C. Kinch, Hendrik Schulze-Koops, Rebecca Germino
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 15(12)
Institutions
Pfizer (United States) (US), Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (AR), Pfizer (Canada) (CA), Hamad Medical Corporation (QA), Ludwig-Maximilians-Universität München (DE), Stanford University (US)